United States
VectraCor is a medical device company that aims to revolutionize the current market for ECG and cardio-pulmonary devices with its disruptive early detection technology and patented innovations. Founded in 2008 and headquartered in the United States, the company holds worldwide patents and has over 40 published papers or abstracts supporting its advancements.
The company's flagship technology involves the development and patenting of a Cardiac Electrical Biomarker (CEB) for real-time detection of ECG changes suggestive of an AMI (acute myocardial infarction), a breakthrough unparalleled in the industry. The VectraplexECG System requires only 5 electrodes (Limbs and V2) to derive a 15-lead ECG in the US and a 22-lead ECG in the EU (CE Mark).
One of VectraCor's most compelling offerings is the VectraplexAMI index, which is displayed in real-time and can prompt an internal and audible alarm if ECG changes suggestive of an AMI are detected. This prompts the display/print-out of the derived 12-22 lead ECG and urges the user to acquire a standard 12-lead ECG for physician interpretation, utilizing the same system.
Overall, VectraCor's dedication to innovation and improvement within the cardiology and emergency medicine marketplace positions it as a key player in the transformation of ECG technology and the monitoring market. With its groundbreaking technology and solid reputation, the company offers substantial potential for investment and further industry disruption.
